Skip to Content

The AKT inhibitor ipatasertib in combination with abiraterone shows promising results in castration-resistant prostate cancer

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top